Compounds and methods for treatment and prevention of Flavivirus infection

US10940188B2 · kind B2 · utility

Assignees

• Florida State University Research Foundation, Inc. · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Hengli Tang · Tallahassee, US
• Emily M. Lee · Tallahassee, US
• YICHEN CHENG · Tallahassee, US
• Yi Zhou · Tallahassee, US
• Wei Zheng · Rockville, US
• Ruili Huang · Rockville, US
• Miao Xu · Hangzhou City, CN
• Wenwei Huang · Rockville, US
• Menghang Xia · Rockville, US
• Hongjun Song · Madison, US
• Guo-li Ming · Village of La Jolla, US
• ZHEXING WEN · Atlanta, US

Key dates

• Filing date: Jan 31, 2020
• Grant date: Mar 9, 2021
• Expiry date: Jan 31, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention concerns the use of compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering a compound or class of compound disclosed herein, such as a niclosamide compound, an emricasan compound, a cyclin-dependent kinase inhibitor, a proteasome inhibitor, or a combination of two or more of the foregoing, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.